Literature DB >> 15596151

Mitochondrial ND5 mutations in idiopathic Parkinson's disease.

W Davis Parker1, Janice K Parks.   

Abstract

Idiopathic Parkinson's disease (PD) is characterized by a systemic loss of activity of complex I (NADH:ubiquinone oxidoreductase), the target enzyme of the parkinsonism producing neurotoxin, MPTP. Cybrid experiments strongly suggest that the loss of complex I activity arises from mitochondrial DNA. We prospectively evaluated low frequency, amino acid changing, heteroplasmic mutations in a narrow region of ND5, a mitochondrial gene encoding a complex I subunit, in brain tissue from PD and controls. The presence or absence of amino acid changing mutations correctly classified 15 of 16 samples. Heteroplasmic mutations in a specific region of ND5 largely segregate PD from controls and may be of major pathogenic importance in idiopathic PD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15596151     DOI: 10.1016/j.bbrc.2004.11.093

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  44 in total

Review 1.  Mitochondrial complex I: structure, function and pathology.

Authors:  Rolf J R J Janssen; Leo G Nijtmans; Lambert P van den Heuvel; Jan A M Smeitink
Journal:  J Inherit Metab Dis       Date:  2006-07-11       Impact factor: 4.982

2.  De novo COX2 mutation in a LHON family of Caucasian origin: implication for the role of mtDNA polymorphism in human pathology.

Authors:  Sergey I Zhadanov; Vasiliy V Atamanov; Nikolay I Zhadanov; Theodore G Schurr
Journal:  J Hum Genet       Date:  2006-01-18       Impact factor: 3.172

3.  Complex I deficiency in Parkinson's disease frontal cortex.

Authors:  W Davis Parker; Janice K Parks; Russell H Swerdlow
Journal:  Brain Res       Date:  2007-11-01       Impact factor: 3.252

Review 4.  Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis.

Authors:  Rebecca Banerjee; Anatoly A Starkov; M Flint Beal; Bobby Thomas
Journal:  Biochim Biophys Acta       Date:  2008-11-14

5.  Mitochondrial gene therapy augments mitochondrial physiology in a Parkinson's disease cell model.

Authors:  Paula M Keeney; Caitlin K Quigley; Lisa D Dunham; Christina M Papageorge; Shilpa Iyer; Ravindar R Thomas; Kathleen M Schwarz; Patricia A Trimmer; Shaharyar M Khan; Francisco R Portell; Kristen E Bergquist; James P Bennett
Journal:  Hum Gene Ther       Date:  2009-08       Impact factor: 5.695

Review 6.  The mitochondrial impairment, oxidative stress and neurodegeneration connection: reality or just an attractive hypothesis?

Authors:  Hirokazu Fukui; Carlos T Moraes
Journal:  Trends Neurosci       Date:  2008-04-09       Impact factor: 13.837

7.  Maternal inheritance and mitochondrial DNA variants in familial Parkinson's disease.

Authors:  David K Simon; Nathan Pankratz; Diane K Kissell; Michael W Pauciulo; Cheryl A Halter; Alice Rudolph; Ronald F Pfeiffer; William C Nichols; Tatiana Foroud
Journal:  BMC Med Genet       Date:  2010-04-01       Impact factor: 2.103

Review 8.  The neurodegenerative mitochondriopathies.

Authors:  Russell H Swerdlow
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

Review 9.  Mitochondria, OxPhos, and neurodegeneration: cells are not just running out of gas.

Authors:  Estela Area-Gomez; Cristina Guardia-Laguarta; Eric A Schon; Serge Przedborski
Journal:  J Clin Invest       Date:  2019-01-02       Impact factor: 14.808

Review 10.  Current perspective of mitochondrial biology in Parkinson's disease.

Authors:  Navneet Ammal Kaidery; Bobby Thomas
Journal:  Neurochem Int       Date:  2018-03-14       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.